These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20110811)

  • 21. A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease.
    Ronco P; Debiec H
    Pflugers Arch; 2017 Aug; 469(7-8):997-1005. PubMed ID: 28597189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.
    Debiec H; Ronco P
    N Engl J Med; 2011 Feb; 364(7):689-90. PubMed ID: 21323563
    [No Abstract]   [Full Text] [Related]  

  • 24. Unmet challenges in membranous nephropathy.
    Salant DJ
    Curr Opin Nephrol Hypertens; 2019 Jan; 28(1):70-76. PubMed ID: 30451735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen.
    Škoberne A; Behnert A; Teng B; Fritzler MJ; Schiffer L; Pajek J; Lindič J; Haller H; Schiffer M
    Eur J Clin Invest; 2014 Aug; 44(8):753-65. PubMed ID: 24942189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients.
    Ronco P; Debiec H
    Mol Immunol; 2015 Nov; 68(1):57-62. PubMed ID: 26597209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Podocyte antigens and glomerular disease.
    Ronco P; Debiec H
    Nephron Exp Nephrol; 2007; 107(2):e41-6. PubMed ID: 17726340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Preliminary results of research on a new marker of idiopathic membranous nephropathy: anti-PLA2R].
    Kozioł M; Sikora A; Kozioł-Montewka M; Smarz-Widelska I; Orłowska-Kowalik G; Pyszna W; Załuska W; Ksiazek A
    Pol Merkur Lekarski; 2014 Mar; 36(213):171-4. PubMed ID: 24779214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Membranous nephropathy: from models to man.
    Beck LH; Salant DJ
    J Clin Invest; 2014 Jun; 124(6):2307-14. PubMed ID: 24892704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological treatment of primary membranous nephropathy in 2016.
    van de Logt AE; Hofstra JM; Wetzels JF
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1463-1478. PubMed ID: 27535699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men.
    Ronco P; Debiec H
    Semin Immunopathol; 2007 Nov; 29(4):445-58. PubMed ID: 17899086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances and prognosis in idiopathic membranous nephropathy.
    Segal PE; Choi MJ
    Adv Chronic Kidney Dis; 2012 Mar; 19(2):114-9. PubMed ID: 22449349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Membranous glomerulonephritis--recent advances in pathogenesis and treatment].
    Horvatić I; Galesić K
    Lijec Vjesn; 2012; 134(11-12):328-39. PubMed ID: 23401979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy.
    Cravedi P; Ruggenenti P; Remuzzi G
    J Am Soc Nephrol; 2011 Aug; 22(8):1400-2. PubMed ID: 21784892
    [No Abstract]   [Full Text] [Related]  

  • 35. Membranous nephropathy as a manifestation of graft-versus-host disease: association with HLA antigen typing, phospholipase A2 receptor, and C4d.
    Byrne-Dugan CJ; Collins AB; Lam AQ; Batal I
    Am J Kidney Dis; 2014 Dec; 64(6):987-93. PubMed ID: 25304985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy.
    Obrisca B; Ismail G; Jurubita R; Baston C; Andronesi A; Mircescu G
    Biomed Res Int; 2015; 2015():249740. PubMed ID: 26576418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fetomaternal alloimmunization with antenatal glomerulopathies.
    Debiec H; Ronco P
    Ann N Y Acad Sci; 2007 Sep; 1110():559-66. PubMed ID: 17911472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crystal structure of the CTLD7 domain of human M-type phospholipase A2 receptor.
    Yu B; Hu Z; Kong D; Cheng C; He Y
    J Struct Biol; 2019 Sep; 207(3):295-300. PubMed ID: 31271865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy.
    Caza TN; Al-Rabadi LF; Beck LH
    Front Immunol; 2021; 12():800242. PubMed ID: 34899763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Idiopathic and secondary membranous nephropathies].
    Ronco P; Debiec H
    Presse Med; 2012 Mar; 41(3 Pt 1):290-7. PubMed ID: 22208961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.